Overview

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Status:
Completed

Trial end date:
2018-05-04

Target enrollment:

Participant gender:

Summary

This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-dose combination 1 inhalation once daily in Patients with moderate to very severe COPD.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Center for Information & Study on Clinical Research Participation (CISCRP)
Cognizant Technology Solution
Corporate Translations Inc
eResearchTechnology
Parexel International Ltd
QuintilesIMS Limited

Treatments:

Formoterol Fumarate
Glycopyrrolate